Search

BaFin Audits Gerresheimer AG Financial Statements

Germany's BaFin has expanded an audit of Gerresheimer AG's 2023/24 financial statements and initiated a new audit of its interim financial statements as of May 31, 2025. The audits are investigating potential misstatements in risk assessments, asset impairment, revenue recognition, lease liabilities, and development costs.

State v. Campos - Probation Revocation and Restitution Appeal

The Idaho Court of Appeals affirmed the revocation of Marlo Raymond Campos's probation but reversed and remanded the order for restitution. The original opinion dated November 14, 2025, was withdrawn and replaced by this substitute opinion filed on March 9, 2026.

State of Idaho v. Allen Paul Troup - Criminal Appeal

The Idaho Court of Appeals affirmed the district court's judgments of conviction and sentences for Allen Paul Troup for possession of a controlled substance. Troup appealed the denial of his motion to suppress and argued his sentence was excessive.

CMA Finalizes Water Company Bill Increases

The UK's Competition and Markets Authority (CMA) has issued a final decision on disputed price controls for five water companies, allowing an average bill increase of 2.2%. The CMA rejected 83% of the increases sought by the companies, granting £463 million in additional revenue, down from a provisional £556 million.

FDA Warning Letter to Peaks Curative for False Claims

The FDA issued a warning letter to Peaks Curative, LLC for making false and misleading claims on its website regarding compounded semaglutide products. The agency found that the company misrepresented its compounding practices and implied FDA approval for products that are not FDA-approved, leading to misbranding violations.

FDA Warning Letter to Lean Rx Inc. dba SkinnyRx

The FDA issued a warning letter to Lean Rx Inc. dba SkinnyRx for misbranding compounded semaglutide and tirzepatide products. The agency cited false or misleading claims on the company's website regarding the compounding of these drugs and their relation to FDA-approved medications.

FDA Warning Letter to Good Girl LLC for False Claims

The FDA issued a warning letter to Good Girl LLC (dba GoodGirlRX) for making false and misleading claims on its website regarding compounded semaglutide and tirzepatide products. The company claimed the products were 'FDA-approved' and that GoodGirl RX was the compounder, which the FDA states is false and misbrands the drugs.

FDA Warning Letter to Refills Health for False Claims

The FDA issued a warning letter to Refills Health, LLC for making false and misleading claims on its website regarding compounded semaglutide products. The agency found that the company misrepresented itself as the compounder and made unsubstantiated claims such as 'clinically proven,' leading to the products being considered misbranded under the FDCA.

FDA Warning Letter to PharmaZee for False Claims

The FDA issued a warning letter to PharmaZee for making false and misleading claims on its website regarding compounded semaglutide and tirzepatide products. The agency found that PharmaZee misrepresented itself as the compounder and implied FDA approval for these unapproved drugs, violating the Federal Food, Drug, and Cosmetic Act.

FDA Warning Letter to Ivim Services LLC for Misbranded Drugs

The FDA issued a warning letter to Ivim Services LLC for introducing misbranded compounded semaglutide and tirzepatide products into interstate commerce. The agency found that Ivim's website made false or misleading claims, suggesting Ivim was the compounder when it was not, violating the Federal Food, Drug, and Cosmetic Act.